|
66 Companies |
|
64 Products |
|
64 Products |
|
38 Mechanisms of Action |
|
0 Trials |
|
1523 News |
|
| «12...4567891011121314...3031» |
- Clinical: GSH Supplementation on Cold/Flu Symptoms in Older Healthy Adults (clinicaltrials.gov) - Dec 16, 2014
P=N/A, N=120, Not yet recruiting, Sponsor: University of Florida
- ||| Enrollment closed: Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults (clinicaltrials.gov) - Dec 14, 2014
P2, N=400, Active, not recruiting, Sponsor: Novavax
Recruiting --> Active, not recruiting
- ||||| Flublok Quadrivalent (influenza vaccine) / Sanofi
Enrollment closed: Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age (clinicaltrials.gov) - Dec 14, 2014
P3, N=1350, Active, not recruiting, Sponsor: Protein Sciences Corporation
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Trial completion, Trial primary completion date: CMC (Carpometacarpal) OA (Osteoarthritis) Thumb Splint Study (clinicaltrials.gov) - Dec 12, 2014
P2, N=56, Completed, Sponsor: University of British Columbia
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Jun 2012 --> Jun 2009
- |||| Trial completion: Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old (clinicaltrials.gov) - Dec 12, 2014
P1/2, N=672, Completed, Sponsor: Novartis Vaccines
Recruiting --> Completed | Trial primary completion date: Jun 2012 --> Jun 2009 Active, not recruiting --> Completed
- Clinical: Prospective Cohort Study to Evaluate Safety/Immunogenicity of Butantan Influenza Vaccine in Healthy Adults/Elderly (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=120, Not yet recruiting, Sponsor: Butantan Institute
- | Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
New P4 trial: Duration of Immune Response to Influenza Vaccination in Patients With RA (clinicaltrials.gov) - Dec 10, 2014
P4, N=90, Active, not recruiting, Sponsor: Bassett Healthcare
- Trial primary completion date: DNA-based Influenza Vaccine in the Elderly (clinicaltrials.gov) - Dec 10, 2014
P1, N=50, Active, not recruiting, Sponsor: University of Manitoba
Active, not recruiting --> Completed Trial primary completion date: Jul 2013 --> Aug 2014
- ||||| New P1/2 trial: Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults (clinicaltrials.gov) - Dec 10, 2014
P1/2, N=110, Not yet recruiting, Sponsor: Takeda
- tamoxifen / Generic mfg.
Trial completion: LOGRIBMET: Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=115, Completed, Sponsor: University of Michigan Cancer Center
Trial primary completion date: Jul 2013 --> Aug 2014 Active, not recruiting --> Completed
- | Trial completion, Enrollment change: ICC H1: Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum (clinicaltrials.gov) - Dec 10, 2014
P1, N=37, Completed, Sponsor: Vaxart
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=12 --> 37
- | Trial completion, Trial primary completion date: ICC H5: Immunogenicity of ND1.1 by Delivery Directly to the Ileum (clinicaltrials.gov) - Dec 10, 2014
P1, N=12, Completed, Sponsor: Vaxart
Active, not recruiting --> Completed | N=12 --> 37 Recruiting --> Completed | Trial primary completion date: Apr 2013 --> Nov 2013
- | Trial completion, Trial primary completion date, Viral vector: Safety Study of an Oral Vaccine to Prevent Seasonal Influenza (clinicaltrials.gov) - Dec 10, 2014
P1, N=37, Completed, Sponsor: Vaxart
Recruiting --> Completed | Trial primary completion date: Apr 2013 --> Nov 2013 Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jan 2014
- ||||| Fluarix Quadrivalent (influenza vaccine) / GSK
Enrollment closed: Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older (clinicaltrials.gov) - Dec 9, 2014
P3, N=356, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jan 2014 Recruiting --> Active, not recruiting
- Vimizim (elosulfase alfa) / BioMarin
Trial termination, Trial primary completion date: Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation (clinicaltrials.gov) - Dec 9, 2014
P2, N=15, Terminated, Sponsor: BioMarin Pharmaceutical
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated | Trial primary completion date: Jul 2016 --> Oct 2014
- || Trial initiation date, Trial primary completion date: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age (clinicaltrials.gov) - Dec 9, 2014
P1, N=420, Not yet recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Terminated | Trial primary completion date: Jul 2016 --> Oct 2014 Initiation date: Oct 2016 --> Mar 2016 | Trial primary completion date: Dec 2016 --> Jun 2016
- Fluvirin (inactivated influenza virus vaccine) / CSL Behring, Fluzone (influenza vaccine) / Sanofi
Phase classification: Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy (clinicaltrials.gov) - Dec 9, 2014
P0, N=21, Terminated, Sponsor: Washington University School of Medicine
Initiation date: Oct 2016 --> Mar 2016 | Trial primary completion date: Dec 2016 --> Jun 2016 Phase classification: P=N/A --> P0
- |||| Trial completion: A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subjects (clinicaltrials.gov) - Dec 7, 2014
P1/2, N=55, Completed, Sponsor: Takeda
Phase classification: P=N/A --> P0 Recruiting --> Completed
- ||||| New P2 trial: Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults (clinicaltrials.gov) - Dec 6, 2014
P2, N=400, Recruiting, Sponsor: Novavax
- || Enrollment closed: Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above (clinicaltrials.gov) - Dec 6, 2014
P1, N=196, Active, not recruiting, Sponsor: Novartis
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Trial completion, Trial primary completion date: Intradermal Influenza Vaccine in the Young (clinicaltrials.gov) - Dec 6, 2014
P3, N=160, Completed, Sponsor: The University of Hong Kong
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Mar 2015 --> Nov 2014
- || oseltamivir / Generic mfg.
Phase classification, Trial primary completion date: IRIS: Influenza Resistance Information Study (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=1200, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | Trial primary completion date: Mar 2015 --> Nov 2014 Phase classification: P4 --> P=N/A | Trial primary completion date: Dec 2013 --> Oct 2015
- |||||| Enrollment open: Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children (clinicaltrials.gov) - Dec 5, 2014
P3, N=660, Recruiting, Sponsor: Novartis
Phase classification: P4 --> P=N/A | Trial primary completion date: Dec 2013 --> Oct 2015 Not yet recruiting --> Recruiting
- Enrollment open, Trial primary completion date: Arm Pump in Motorcross Training (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=40, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2014 --> Dec 2014
- |||| Trial completion, Preclinical: Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine) (clinicaltrials.gov) - Dec 5, 2014
P1/2, N=84, Completed, Sponsor: Green Cross Corporation
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2014 --> Dec 2014 Not yet recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: The Role of Influenza as a Trigger for Acute Myocardial Infarction: a CALIBER Study (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=11208, Completed, Sponsor: University College, London
Not yet recruiting --> Completed Active, not recruiting --> Completed | N=20000 --> 11208 | Trial primary completion date: Dec 2013 --> Oct 2012
- Enrollment closed: SOP Toolkit in Diverse Practices Implemented & Tested With RE-AIM (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=596, Active, not recruiting, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed | N=20000 --> 11208 | Trial primary completion date: Dec 2013 --> Oct 2012 Enrolling by invitation --> Active, not recruiting
- Enrollment closed: A Phase I Study of Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1 (clinicaltrials.gov) - Dec 5, 2014
P1, N=72, Active, not recruiting, Sponsor: University of Oxford
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine ChAdOx1-NP+M1 (clinicaltrials.gov) - Dec 5, 2014
P1, N=15, Completed, Sponsor: University of Oxford
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: Effects of BCG on Influenza Induced Immune Response (clinicaltrials.gov) - Nov 28, 2014
P2/3, N=40, Completed, Sponsor: Radboud University
Active, not recruiting --> Completed Recruiting --> Completed
- Trial completion: A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge Model (clinicaltrials.gov) - Nov 28, 2014
P2, N=101, Completed, Sponsor: Genentech, Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- | lenalidomide / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Nov 25, 2014
P2, N=35, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Feb 2015 --> Nov 2014 | Trial primary completion date: Feb 2018 --> Nov 2017
- Enrollment change: From Innovation to Solutions: Childhood Influenza Vaccination Planning (clinicaltrials.gov) - Nov 24, 2014
P=N/A, N=87665, Completed, Sponsor: University of Pittsburgh
Not yet recruiting --> Recruiting | Initiation date: Feb 2015 --> Nov 2014 | Trial primary completion date: Feb 2018 --> Nov 2017 N=150 --> 87665
- || Trial initiation date, Trial primary completion date: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age (clinicaltrials.gov) - Nov 24, 2014
P1, N=420, Not yet recruiting, Sponsor: GlaxoSmithKline
N=150 --> 87665 Initiation date: Dec 2015 --> Oct 2016 | Trial primary completion date: Feb 2016 --> Dec 2016
- || Ampligen (rintatolimod) / AIM ImmunoTech
Trial primary completion date: Safety Study of FluMist With and Without Ampligen (clinicaltrials.gov) - Nov 24, 2014
P1/2, N=72, Recruiting, Sponsor: Hemispherx Biopharma
Initiation date: Dec 2015 --> Oct 2016 | Trial primary completion date: Feb 2016 --> Dec 2016 Trial primary completion date: Mar 2015 --> Jun 2015
- New P1 trial: Safety and Pharmacokinetics Study of FBF001 (clinicaltrials.gov) - Nov 20, 2014
P1, N=16, Completed, Sponsor: Fab'entech
- Clinical: Study of the Immune Response After Vaccination in Multiple Myeloma Patients (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=80, Not yet recruiting, Sponsor: Michael A. Thompson, MD, PhD
- Clinical: Fever and Wheezing Events in Children After US Influenza Vaccines Using Text Messaging (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=150, Not yet recruiting, Sponsor: Columbia University
- | lenalidomide / Generic mfg.
Trial initiation date, Trial primary completion date: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Nov 19, 2014
P2, N=35, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Mar 2015 --> Jun 2015 Initiation date: Nov 2014 --> Feb 2015 | Trial primary completion date: Nov 2017 --> Feb 2018
- | New P2 trial, Combination therapy: A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection (clinicaltrials.gov) - Nov 18, 2014
P2, N=334, Recruiting, Sponsor: Genentech, Inc.
- | M-001 / BiondVax
New P2 trial: Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV (clinicaltrials.gov) - Nov 18, 2014
P2, N=36, Recruiting, Sponsor: BiondVax Pharmaceuticals ltd.
- oseltamivir / Generic mfg.
Trial primary completion date: Rapid Empiric Treatment With Oseltamivir Study (RETOS) (clinicaltrials.gov) - Nov 18, 2014
P4, N=1000, Enrolling by invitation, Sponsor: University of Louisville
Initiation date: Nov 2014 --> Feb 2015 | Trial primary completion date: Nov 2017 --> Feb 2018 Trial primary completion date: May 2014 --> May 2015
- Plegridy (PEG-interferon ?-1a) / Biogen
Enrollment change, Trial withdrawal: Frequency: Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy (clinicaltrials.gov) - Nov 17, 2014
P4, N=0, Withdrawn, Sponsor: Biogen Idec
Trial primary completion date: May 2014 --> May 2015 N=1200 --> 0 | Not yet recruiting --> Withdrawn
- ||||| Plegridy (PEG-interferon ?-1a) / Biogen
Enrollment closed, Trial primary completion date: Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-?) Therapies to Peginterferon Beta-1a (BIIB017) (clinicaltrials.gov) - Nov 17, 2014
P3, N=200, Active, not recruiting, Sponsor: Biogen Idec
N=1200 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Nov 2015
- ||| Trial completion: Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age (clinicaltrials.gov) - Nov 17, 2014
P1, N=427, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Nov 2015 Active, not recruiting --> Completed
- ||| Enrollment open, Pneumococcal vaccines: System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts (clinicaltrials.gov) - Nov 16, 2014
P=N/A, N=30000, Enrolling by invitation, Sponsor: University of Massachusetts, Worcester
Active, not recruiting --> Completed Not yet recruiting --> Enrolling by invitation
- ||||| New P4 trial: IIJI: Inactivated Influenza Via Jet Injection (clinicaltrials.gov) - Nov 14, 2014
P4, N=900, Recruiting, Sponsor: PharmaJet, Inc.
- |||||||||| Flublok Quadrivalent (influenza vaccine) / Sanofi
New P3 trial: Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age (clinicaltrials.gov) - Nov 14, 2014
P3, N=1350, Recruiting, Sponsor: Protein Sciences Corporation
- |||| Trial primary completion date: Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu (clinicaltrials.gov) - Nov 13, 2014
P3, N=244, Recruiting, Sponsor: Novartis
Not yet recruiting --> Enrolling by invitation Trial primary completion date: May 2015 --> Aug 2015
- ||||| oseltamivir / Generic mfg., nitazoxanide / Generic mfg.
Enrollment change, Trial primary completion date: Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza (clinicaltrials.gov) - Nov 12, 2014
P3, N=2300, Recruiting, Sponsor: Romark Laboratories L.C.
Trial primary completion date: May 2015 --> Aug 2015 N=1800 --> 2300 | Trial primary completion date: Dec 2014 --> May 2015